BioMarin announced a $70 million payment to expand its Fabry enzyme replacement portfolio by acquiring rights to a long-acting Fabry drug, positioning the company for dosing advantages over existing products. The transaction is notable because it may broaden treatment options for patients who may not be eligible for earlier Fabry therapies. The move comes as BioMarin continues to deepen its enzyme replacement pipeline and portfolio breadth in rare genetic diseases. For investors and partners, it also signals continued willingness to pay for next-generation improvements in dosing durability and real-world usability. BioMarin’s expansion could also reshape competitive dynamics among Fabry ERT suppliers, given how administration burden and adherence can affect long-term outcomes and market share.